Results 51 to 60 of about 7,354 (172)

ePS6.08 Second-hand smoke exposure reduces the clinical efficacy of ivacaftor in G551D: results from the GOAL study [PDF]

, 2022
S.M. Rowe, G.R. Oates, E. Baker, S.V. Raju, W.T. Harris   +4 more
openalex   +1 more source

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model

Clinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Elexacaftor/tezacaftor/ivacaftor (ETI), a cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, has provided great improvements in lung function and well‐being for people with CF. The use of ETI has been complicated by reports of rare but significant liver function test elevations in clinical trials and drug‐induced ...
Alan Shi, Palak Agarwal, Zhang‐Xu Liu, Paul M. Beringer   +3 more
wiley   +1 more source

The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report

BMC Gastroenterology, 2019
Background Cystic fibrosis (CF) is a genetic disorder of the epithelial CFTR apical chloride channel resulting in multi-organ manifestations, including pancreatic exocrine secretion.
J. Dixon Johns, Steven M. Rowe
doaj   +1 more source

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

Frontiers in Pharmacology, 2023
Triple combination therapy with the CFTR modulators elexacaftor (ELX), tezacaftor (TEZ) and ivacaftor (IVA) has been qualified as a game changer in cystic fibrosis (CF).
Burkhard Tümmler, Burkhard Tümmler
doaj   +1 more source

P151 Pregnancies with elexacaftor/tezacaftor/ivacaftor in Argentina [PDF]

, 2023
E. Baran, L. Osken, N. Bergas Gimbernat
openalex   +1 more source

Functional Pulmonary Imaging

Journal of Magnetic Resonance Imaging, Volume 62, Issue 4, Page 986-1008, October 2025.
ABSTRACT The aging of the world population gave rise to an increased prevalence of many lung diseases, with chronic obstructive pulmonary disease now ranking as the third‐leading cause of death according to the World Health Organization. To diagnose lung disease, a thorough assessment of lung function is essential since it may reveal unique signatures ...
Agilo L. Kern, Filip Klimeš, Andreas Voskrebenzev, Hoen‐Oh Shin, Jens Vogel‐Claussen   +4 more
wiley   +1 more source

Phenotype‐Genotype Correlations in ABCA3 Patients—The RespiRare Cohort

Pediatric Pulmonology, Volume 60, Issue 10, October 2025.
ABSTRACT Background ATP‐binding cassette transporter A3 (ABCA3) deficiency is one of the most severe causes of childhood interstitial lung diseases (chILD). This study aims to report the RespiRare ABCA3 cohort and to establish phenotype‐genotype correlations. Methods Phenotypic and genotypic data of patients under 18 years were retrospectively included
Manon Fleury, Céline Delestrain, Alice Hadchouel, Julie Mazenq, Myriam Benhamida, Anne‐Sophie Bernard, Raphaël Borie, Jacques Brouard, Harriet Corvol, Pierrick Cros, Christophe Delacourt, Tifenn Desroziers, Jean‐Christophe Dubus, Carole Egron, Ralph Epaud, Michael Fayon, Aude Forgeron, Lisa Giovannini‐Chami, Christophe Marguet, Alexandra Masson‐Rouchaud, Hortense Petat, Marie‐Catherine Renoux, Léa Roditis, Caroline Thumerelle, Clémentine Vigier, Aurore Coulomb L'Herminé, Hubert Ducou le Pointe, Pascale Fanen, Camille Fletcher, Chiara Sileo, Laureline Berteloot, Camille Louvrier, Alix de Becdelièvre, Marie Legendre, Nadia Nathan   +34 more
wiley   +1 more source

EPS6.03 Pulmonary pathogen prevalence 12 months after elexacaftor/tezacaftor/ivacaftor introduction: results from the Danish National Cystic Fibrosis Cohort [PDF]

, 2023
M. Jeppesen, S. Jensen-Fangel, Camilla Bjørn Jensen, Terese L. Katzenstein, M. Wang, M. Frahm Olesen, T. Pressler, Marianne Skov, Hanne Vebert Olesen, Tavs Qvist   +9 more
openalex   +1 more source

The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution

Clinical Transplantation, Volume 39, Issue 10, October 2025.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically changed the landscape of cystic fibrosis (CF) care, including in those who require lung transplantation. The objectives of the study were to describe the cohort demographics and outcomes of primary lung transplant recipients before and after the availability of ETI.
Julie Semenchuk, Eliza Tuff‐Gordon, Xiayi Ma, Jenna Sykes, Stephanie Y. Cheng, Meghan Aversa, Cecilia Chaparro, Elizabeth Tullis, Anne L. Stephenson   +8 more
wiley   +1 more source

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis

Magnetochemistry, 2020
Magnetic nanoparticles have been largely applied to increase the efficacy of antibiotics due to passive accumulation provided by enhancing permeability and retention, which is essential for the treatment of lung infections. Recurring lung infections such
Marsha Tan, Felisa Reyes-Ortega, Elena K. Schneider-Futschik   +2 more
doaj   +1 more source